Study guide
6.2 Heart Failure & Cardiomyopathies
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
6.2 Heart Failure & Cardiomyopathies
Key Takeaways Explain This Topic AI
The Universal Definition classifies heart failure into HFrEF (LVEF <=40%), HFmrEF (LVEF 41-49%), and HFpEF (LVEF >=50%); NT-proBNP >2000 pg/mL mandates urgent specialist assessment and transthoracic echocardiography within 2 weeks under NICE guidelines.
Guideline-Directed Medical Therapy (GDMT) for HFrEF comprises four foundational mortality-reducing pillars: an ARNI/ACEi, an evidence-based beta-blocker (bisoprolol, carvedilol, metoprolol succinate, nebivolol), an MRA (spironolactone, eplerenone), and an SGLT2 inhibitor (dapagliflozin, empagliflozin).
When switching from an ACE inhibitor to sacubitril/valsartan (ARNI), a mandatory 36-hour washout period is required to prevent life-threatening bradykinin-mediated angioedema caused by simultaneous ACE and neprilysin inhibition.
Hypertrophic cardiomyopathy is predominantly caused by autosomal dominant mutations in sarcomeric genes (MYH7, MYBPC3); its dynamic LVOT obstruction is exacerbated by medications that reduce preload or afterload (nitrates, ACE inhibitors, dihydropyridine CCBs) and relieved by beta-blockers.
Cardiac amyloidosis presents as restrictive cardiomyopathy with low ECG voltages paradoxical to thick ventricular walls; bone scintigraphy (99mTc-DPD/PYP) establishes non-invasive diagnosis of ATTR amyloidosis in the absence of clonal light chains.
Last updated: September 2026
Heart failure (HF) represents a clinical syndrome characterized by cardinal symptoms (breathlessness, fatigue, ankle swelling) and objective structural or functional cardiac abnormalities. For MRCP(UK) Part 1, candidates must master the diagnostic thresholds for natriuretic peptides, evidence-based pharmacology across the ejection fraction spectrum, device indications, and the distinct phenotypes of inherited and acquired cardiomyopathies.
- 1. Classification & Diagnostic Evaluation of Heart Failure
- Universal Definition & Ejection Fraction Categories
The international consensus defines heart failure according to left ventricular ejection fraction (LVEF):
HFrEF (Heart Failure with reduced Ejection Fraction): LVEF ≤ 40 % \text{LVEF} \le 40\% LVEF ≤ 40% . Characterized by ventricular dilatation, progressive eccentric remodelling, and marked activation of the sympathetic and renin-angiotensin-aldosterone systems (RAAS).
HFmrEF (Heart Failure with mildly reduced Ejection Fraction): LVEF 41 – 49 % \text{LVEF } 41\text{–}49\% LVEF 41 – 49% . Shares phenotypic traits with both HFrEF and HFpEF; post-hoc analyses show significant benefit from HFrEF neurohormonal therapies.
HFpEF (Heart Failure with preserved Ejection Fraction): LVEF ≥ 50 % \text{LVEF} \ge 50\% LVEF ≥ 50% . Characterized by impaired diastolic relaxation, increased passive myocardial stiffness, left ventricular hypertrophy (LVH), and left atrial hypertension.
Natriuretic Peptides: Diagnostic Thresholds & Caveats
Myocytes release B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in response to increased myocardial wall stretch and transmural pressure.
NICE Referral Pathways:
NT-proBNP > 2000 pg/mL \text{NT-proBNP} > 2000\text{ pg/mL} NT-proBNP > 2000 pg/mL ( > 236 pmol/L > 236\text{ pmol/L} > 236 pmol/L ): Urgent specialist clinical assessment and transthoracic echocardiography (TTE) within 2 weeks .
NT-proBNP 400 – 2000 pg/mL \text{NT-proBNP } 400\text{–}2000\text{ pg/mL} NT-proBNP 400 – 2000 pg/mL ( 47 – 236 pmol/L 47\text{–}236\text{ pmol/L} 47 – 236 pmol/L ): Specialist assessment and TTE within 6 weeks .
NT-proBNP < 400 pg/mL \text{NT-proBNP} < 400\text{ pg/mL} NT-proBNP < 400 pg/mL ( < 47 pmol/L < 47\text{ pmol/L} < 47 pmol/L ): Heart failure is highly unlikely (negative predictive value > 95 % > 95\% > 95% ). Consider alternative diagnoses.
Clinical Confounders:
Elevated Levels: Advanced age ( > 75 > 75 > 75 years), female sex, renal impairment (reduced glomerular clearance), atrial fibrillation (continuous atrial stretch), pulmonary embolism, sepsis, severe COPD.
Depressed Levels: Obesity ( BMI ≥ 30 kg/m 2 \text{BMI} \ge 30\text{ kg/m}^2 BMI ≥ 30 kg/m 2 ) reduces circulating natriuretic peptide levels by approximately 30 – 50 % 30\text{–}50\% 30 – 50% due to upregulation of clearance receptors (NPR-C) and blunted cardiac peptide synthesis.
Echocardiographic Diastolic Function Assessment
Diastolic dysfunction underpins HFpEF and is evaluated via transmitral pulsed-wave and tissue Doppler imaging:
Mitral Inflow E/A Ratio: Ratio of peak velocity of early passive filling ( E E E wave) to late atrial contraction ( A A A wave). Normal is 1.0 – 2.0 1.0\text{–}2.0 1.0 – 2.0 . Grade I (impaired relaxation): E / A < 0.8 E/A < 0.8 E / A < 0.8 ; Grade II (pseudonormal): E / A 0.8 – 2.0 E/A\ 0.8\text{–}2.0 E / A 0.8 – 2.0 ; Grade III (restrictive filling): E / A > 2.0 E/A > 2.0 E / A > 2.0 with deceleration time < 140 ms < 140\text{ ms} < 140 ms .
E / e ′ E/e' E / e ′ Ratio: Ratio of mitral inflow E E E velocity to early diastolic mitral annular tissue velocity ( e ′ e' e ′ ). An average E / e ′ > 14 E/e' > 14 E / e ′ > 14 is a robust surrogate for elevated left ventricular end-diastolic pressure (LVEDP) and pulmonary capillary wedge pressure ( > 15 mmHg > 15\text{ mmHg} > 15 mmHg ).
Left Atrial Volume Index (LAVI): LAVI > 34 mL/m 2 \text{LAVI} > 34\text{ mL/m}^2 LAVI > 34 mL/m 2 reflects chronic exposure to elevated left ventricular filling pressures.
2. Guideline-Directed Medical Therapy (GDMT): The Four Pillars of HFrEF
All patients with HFrEF should be rapidly uptitrated onto the "four pillars" of guideline-directed medical therapy, each proven in landmark clinical trials to independently reduce all-cause mortality, cardiovascular death, and heart failure hospitalizations.
Pillar / Drug Class Landmark Trials Specific Agents & Target Doses Mechanism of Action Monitoring & Critical Cautions
1. ARNI (or ACEi / ARB) PARADIGM-HF (ARNI); CONSENSUS, SOLVD (ACEi) Sacubitril/Valsartan (ARNI: 24/26 mg to 97/103 mg bd); Ramipril (10 mg od), Enalapril (10 mg bd) Sacubitril inhibits neprilysin (preventing breakdown of natriuretic peptides, bradykinin, adrenomedullin); valsartan blocks AT 1 \text{AT}_1 AT 1 receptors Mandatory 36-hour washout when switching from ACEi to ARNI to prevent life-threatening angioedema. Check K + \text{K}^+ K + and creatinine at 1–2 weeks
2. Evidence-Based Beta-Blocker CIBIS-II (Bisoprolol); COPERNICUS (Carvedilol); MERIT-HF (Metoprolol succinate) Bisoprolol (10 mg od), Carvedilol (25–50 mg bd), Metoprolol succinate MR (200 mg od), Nebivolol (10 mg od) Blocks chronic maladaptive sympathetic stimulation, reverses LV remodelling, reduces sudden arrhythmic death Initiate only when clinically euvolaemic. "Start low, go slow" (double dose q2–4 weeks). Contraindicated in acute decompensation or severe asthma
3. Mineralocorticoid Receptor Antagonist (MRA) RALES (Spironolactone); EMPHASIS-HF (Eplerenone) Spironolactone (25–50 mg od), Eplerenone (50 mg od) Antagonizes aldosterone at mineralocorticoid receptors in distal tubule and myocardium; blunts myocardial fibrosis and potassium wasting Discontinue or halve if K + > 5.5 mmol/L \text{K}^+ > 5.5\text{ mmol/L} K + > 5.5 mmol/L or eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min . Eplerenone avoids gynaecomastia / breast tenderness
4. SGLT2 Inhibitor DAPA-HF (Dapagliflozin); EMPEROR-Reduced (Empagliflozin) Dapagliflozin (10 mg od), Empagliflozin (10 mg od) Inhibits SGLT2 in renal proximal tubule; promotes osmotic diuresis, natriuresis, improves cardiac energetics, lowers preload/afterload Indicated regardless of diabetic status . Negligible hypoglycaemia risk. Watch for euglycaemic DKA and mycotic genital infections
MRCP Exam Pearl: Diuretics: Loop diuretics (furosemide, bumetanide) and thiazides provide essential symptomatic decongestion and preload reduction, but have never been shown to reduce mortality . Always use the lowest dose required to maintain euvolaemia.
- 3. Secondary Pharmacotherapy & Device Indications
- Second-Line Pharmacotherapy
Ivabradine: Selective inhibitor of hyperpolarization-activated cyclic nucleotide-gated ( I f I_f I f ) funny channels in the sinoatrial node, slowing heart rate without negative inotropy. Indications: HFrEF ( LVEF ≤ 35 % \text{LVEF} \le 35\% LVEF ≤ 35% ) in sinus rhythm with resting heart rate ≥ 70 bpm \ge 70\text{ bpm} ≥ 70 bpm despite maximal tolerated beta-blocker therapy (SHIFT trial). Contraindicated in atrial fibrillation.
Hydralazine + Isosorbide Dinitrate (H-ISDN): Arteriolar vasodilator plus venodilator / nitric oxide donor. Indications: Self-identified Black/African-Caribbean patients with persistent NYHA class III–IV symptoms despite optimal 4-pillar GDMT (A-HeFT trial), or patients intolerant to ARNI/ACEi/ARB due to renal dysfunction or severe hyperkalaemia.
Vericiguat: Direct stimulator of soluble guanylate cyclase (sGC), augmenting cyclic GMP signaling. Indicated in high-risk HFrEF with recent worsening heart failure hospitalization or elevated natriuretic peptides despite GDMT (VICTORIA trial).
Digoxin: Inhibits myocardial Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase. Reduces heart failure hospitalizations without altering overall mortality (DIG trial). Narrow therapeutic range ( 0.5 – 0.9 ng/mL 0.5\text{–}0.9\text{ ng/mL} 0.5 – 0.9 ng/mL ); hypokalaemia precipitates life-threatening digoxin toxicity.
Device Therapies: ICD & CRT
Implantable Cardioverter-Defibrillator (ICD):
Primary Prevention: Indicated for patients with LVEF ≤ 35 % \text{LVEF} \le 35\% LVEF ≤ 35% after at least 3 months of optimal medical therapy, NYHA functional class II–III, and good functional status with life expectancy > 1 year > 1\text{ year} > 1 year . In ischaemic cardiomyopathy, ICD implantation must be delayed until at least 40 days post-infarction to exclude recovery.
Cardiac Resynchronisation Therapy (CRT):
Delivers biventricular pacing via leads in the right atrium, right ventricle, and coronary sinus (pacing the left ventricular lateral wall) to eliminate ventricular dyssynchrony.
Indications (NICE / ESC): LVEF ≤ 35 % \text{LVEF} \le 35\% LVEF ≤ 35% , NYHA class II–IV despite optimal medical therapy, in sinus rhythm with QRS duration ≥ 130 ms \text{QRS duration} \ge 130\text{ ms} QRS duration ≥ 130 ms with LBBB morphology (greatest benefit seen when QRS ≥ 150 ms \text{QRS} \ge 150\text{ ms} QRS ≥ 150 ms ). CRT-D incorporates defibrillator capability, whereas CRT-P provides resynchronisation pacing alone.
- 4. Cardiomyopathies: Inherited & Secondary Myocardial Diseases
- Hypertrophic Cardiomyopathy (HCM)
Genetics & Histopathology: Autosomal dominant inheritance with incomplete penetrance. Caused by missense mutations in sarcomeric contractile proteins, predominantly β \beta β -myosin heavy chain ( M Y H 7 MYH7 M Y H 7 , ~35%) and myosin-binding protein C ( M Y B P C 3 MYBPC3 M Y BPC 3 , ~35%) . Histopathology reveals marked myocyte hypertrophy, interstitial fibrosis, and characteristic myocyte disarray (loss of parallel myofibrillar architecture).
Pathophysiology: Asymmetric septal hypertrophy (ASH; ratio of septal to posterior wall thickness > 1.3 > 1.3 > 1.3 ) creates high-velocity systolic ejection, pulling the anterior mitral leaflet into the left ventricular outflow tract ( Systolic Anterior Motion [SAM] via the Venturi effect and flow drag). This causes dynamic LVOT obstruction and eccentric mitral regurgitation.
Auscultation & Dynamic Maneuvers: Harsh crescendo-decrescendo ejection systolic murmur best heard at the lower left sternal border:
Intensified by: Decreased preload or decreased afterload (Valsalva strain, standing, vasodilators, nitrates), which shrink LV cavity dimensions and narrow the outflow tract.
Softened by: Increased preload or increased afterload (squatting, handgrip, passive leg raising), which expand LV dimensions.
Pharmacotherapy & Contraindications: First-line agents are non-vasodilating beta-blockers (bisoprolol, atenolol) or rate-limiting calcium channel blockers (verapamil) to prolong diastole and enhance filling. Mavacamten (cardiac myosin ATPase inhibitor) is licensed for symptomatic obstructive HCM. Strictly contraindicated: Nitrates, ACE inhibitors, dihydropyridine CCBs, and digoxin (exacerbate the dynamic LVOT gradient).
Sudden Cardiac Death (SCD) Risk Stratification: Risk factors include massive LV hypertrophy (maximal wall thickness ≥ 30 mm \ge 30\text{ mm} ≥ 30 mm ), unexplained syncope, non-sustained VT on ambulatory Holter, family history of premature SCD, extensive late gadolinium enhancement ( LGE > 15 % \text{LGE} > 15\% LGE > 15% ) on CMR, and apical LV aneurysm. High-risk patients require primary prevention ICD.
Dilated Cardiomyopathy (DCM)
Etiology: Familial/genetic in up to 40% (mutations in titin [ T T N TTN TTN ] in 25%, lamin A/C [ L M N A LMNA L MN A ] associated with high risk of conduction block and malignant arrhythmias). Acquired causes: viral myocarditis (coxsackie B, parvovirus B19), toxic (chronic alcohol abuse, anthracyclines [doxorubicin], trastuzumab), autoimmune, and peripartum cardiomyopathy.
Echocardiography: Left ventricular dilation with spherical remodelling, eccentric hypertrophy, and diffuse global hypokinesis resulting in severe systolic impairment. Management follows standard HFrEF 4-pillar GDMT and primary prevention ICD.
Restrictive Cardiomyopathy (RCM) & Cardiac Amyloidosis
Pathophysiology: Rigid, non-compliant ventricular myocardium causing severe diastolic filling impairment with normal or near-normal systolic function and preserved ventricular wall thickness (or pseudohypertrophy).
Cardiac Amyloidosis: Infiltration of insoluble fibrillar amyloid deposits:
AL (Light-Chain) Amyloidosis: Clonal plasma cell dyscrasia producing monoclonal kappa or lambda light chains. Rapidly progressive heart failure, macroglossia, periorbital purpura.
ATTR (Transthyretin) Amyloidosis: Wild-type (senile, typically men > 70 > 70 > 70 years) or hereditary (mutations in the T T R TTR TTR gene). Associated with bilateral carpal tunnel syndrome, spinal stenosis, and biceps tendon rupture years prior to cardiac diagnosis.
Diagnostic Signatures:
ECG: Low voltage QRS complexes across limb leads paradoxical to marked ventricular wall thickening on echocardiography ("voltage-mass discordance").
Echocardiography: Granular, sparkling ground-glass myocardial appearance, biatrial enlargement, and longitudinal strain showing apical sparing ("cherry-on-top" pattern) .
Cardiac MRI: Diffuse global subendocardial or transmural late gadolinium enhancement with abnormal myocardial nulling kinetics.
Technetium-99m DPD / PYP Scintigraphy: Intense Grade 2 or 3 cardiac tracer uptake confirms ATTR amyloidosis non-invasively, eliminating the need for endomyocardial biopsy if serum and urine clonal light chains are negative. Tafamidis stabilizes the transthyretin tetramer, improving survival in ATTR.
Biopsy: Demonstrates Congo red staining with pathognomonic apple-green birefringence under polarized light.
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Pathophysiology: Autosomal dominant mutations in desmosomal proteins (plakophilin-2 [ P K P 2 PKP2 P K P 2 ], desmoplakin, plakoglobin [Naxos disease with woolly hair and palmoplantar keratoderma]). Mechanical stress detaches myocytes, leading to fibrofatty replacement of the right ventricular free wall within the "triangle of dysplasia" (RV inflow, apex, and outflow tract).
Clinical & ECG Findings: Palpitations, syncope, and ventricular tachycardia with LBBB morphology and superior axis (arising from the RV free wall). Resting 12-lead ECG demonstrates:
Epsilon wave: Pathognomonic distinct low-amplitude deflection or notch at the terminal end of the QRS complex in leads V1–V3 (present in ~30%).
T-wave inversion in leads V1–V3 in individuals > 14 > 14 > 14 years of age (in the absence of complete RBBB).
Prolonged S-wave upstroke ( ≥ 55 ms \ge 55\text{ ms} ≥ 55 ms ) in V1–V3.
Management: Competitive athletics and endurance sports are strictly prohibited (accelerates disease progression). First-line therapy includes beta-blockers and early ICD implantation for high-risk patients.